Bioequivalence Study of Meloxicam 15 mg Tablet Manufactured by PT. Kimia Farma Tbk Compared to Movi-Cox® 15 mg Tablet Manufactured by PT. Boehringer Ingelheim Indonesia
Tahapan Penelitian : Complete
Sponsor:
PT Kimia Farma Tbk
Mitra Pelaksana:
EQuitrust Lab - PT Kimia Farma Diagnostika
No Registry
INA-ZRSRGQX
Tanggal Input Registry : 04-04-2024
| Tracking Information | |
|---|---|
| Tanggal Antisipasi Studi | 17-01-2022 |
| Outcome Primer | AUC0-t , Cmax |
| Outcome Skunder | AUC0-inf , Tmax, Half life |
| Descriptive Information | |
| Judul Penelitian Popular | Bioequivalence Study of Meloxicam 15 mg Tablet Manufactured by PT. Kimia Farma Tbk Compared to Movi-Cox® 15 mg Tablet Manufactured by PT. Boehringer Ingelheim Indonesia |
| Judul Penelitian Ilmiah | STUDI BIOEKIVALENSI MELOXICAM 15 MG TABLET PRODUKSI PT. KIMIA FARMA Tbk. DIBANDINGKAN DENGAN MOVI-COX® 15 MG TABLET (KOMPARATOR) PRODUKSI PT. BOEHRINGER INGELHEIM INDONESIA |
| Jenis Penelitian | Interventional |
| Intervensi | Meloxicam 15 mg Tablet Manufactured by PT. Kimia Farma Tbk |
| Jumlah Subyek Penelitian | 18 |
| Recruitment Information | |
| Eligibility Criteria | Inclusion Criteria: The inclusion criteria for this study include: 1) Signed informed consent; 2) Healthy based on clinical laboratory tests (routine hematology, liver function, kidney function, blood glucose, urinalysis, hepatitis B (HBsAg), hepatitis C (Anti-HCV), and HIV (Anti-HIV), medical history, and physical examination); 3) Male and female subjects (if female, consider the risks for women of childbearing age and perform pregnancy tests); 4) Age between 18-55 years; 5) Normal weight range according to Body Mass Index (BMI) 18-25 kg/m2); 6) Vital signs within the following ranges: systolic blood pressure 110-129 mmHg, diastolic blood pressure 70-84 mmHg, normal pulse rate 60-90 bpm, oxygen saturation (SpO2) in the normal range of 95-100%, and normal respiratory rate of 12-20/min.Exclusion Criteria: 1) Smoking more than 10 cigarettes per day; 2) Pregnant or breastfeeding women. Pregnancy tests will be performed during screening and prior to the administration of the investigational or comparator drug; 3) History of kidney or liver disease, or history of allergy, hypersensitivity or contraindication to the investigational bioequivalence drug (Ethambutol); 4) Clinically significant hematological abnormalities; 5) Abnormal electrocardiogram (ECG); 6) Difficulty accessing veins in the left or right arm; 7) History of significant ongoing clinically or medically significant chronic or acute illness; 8) History of drug or alcohol abuse within the past 12 months (1 year) prior to screening for this study; 9) Positive serology test results for Hepatitis B (HBsAg), Hepatitis C (anti-HCV), HIV (anti-HIV). 10) Positive rapid antigen test results for SARS-CoV-2 (if the BE study is conducted during a pandemic). 11) History or condition that can affect drug kinetics. 12) Use of drugs or dietary supplements no more than 7 days since the start of the study. 13) Participation in previous clinical trials no more than 3 months from the start of the study. 14) Blood donation or blood loss of more than 300 ml within 3 months from the start of the study. |
| Administrative Information | |
| Nomor Persetujuan Etik | KET-1019/UN2.F1/ETIK/PPM.00.02/2021 |
| Nomor Persetujuan Material Transfer Agreement | Not applicable |
| Nomor Persetujuan Pelaksanaan Uji Klinik | PPUK/PPUB number |
| Other Study ID Numbers | |
| Contact Person | Bayu Hadi Wahyono, Pharm, B.Pham, MPH - Study Coordinator (085773150080 - lab.equitrust@gmail.com) |